Tuesday November 24 2009 | Biotechnology feed | All feeds
|
|
Protox Therapeutics Inc.
Download detailed PDF Members: Protox Therapeutics is a product-focused development-stage company and a leader in advancing novel, targeted protein toxin therapeutics for the treatment of cancer and other proliferative diseases. Through the company’s INxin™ and PORxin™ technology platforms, therapeutic candidates are generated by engineering the naturally occurring toxins, Pseudomonas exotoxin and proaerolysin. These drugs are potent anti-cancer agents with distinct modes of action.INxin™ drugs target cancer cells that produce specific tumor associated receptors on their cell surface. Once bound to the cancer cells, INxin™ drugs enter the cell and inhibit protein synthesis which ultimately leads to cell death. A Phase II clinical trial has been completed with Protox’s lead compound, PRX321, for the treatment of primary brain cancer, specifically recurrent malignant glioblastoma multiforme and astrocytoma. A Phase I clinical trial has also been completed for both renal cell carcinoma and non-small cell lung cancer. PRX321 is also in pre-clinical development for other peripheral solid tumors and hematological tumors
This page has been viewed 448 times since April 2007, the link to the organisation's website has been followed 58 times Recent Search Terms used to find this page: Protox Therapeutics Inc | protox | protox therapeutics | protox therapeutics | protox therapeutics inxin | Protox Th | protox therapeutics | Protox | protox therapeutics | protox therapeutics and vancouver and biotech | . Search for more companies in Vancouver Search for more companies in British Columbia This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Protox Therapeutics Inc. | ||||||||||||||||||||||||||||||
|